Skip to content

艾尔免疫

US · ALT #3727 按市值排名
2.20 -0.16 -6.78%
实时 - 追踪5344个代码 - 心跳于198秒前 · 2026-10-16 19:57

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了2家。
  • 机构持股总比例下降了1.2个百分点。

机构持股

机构持股比例
77.75% -1.23pp
机构数量
241 -2
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund36.49%
VC/PE Fund19.37%
Hedge Fund18.15%
Public Company2.31%
Private Company1.06%
Individual/Insider0.48%
Insurance Company0.23%
Government Pension Fund0.10%
Other21.78%

主要股东 截至 2026-06-30

BlackRock 10.48% · 20.39M 股
Deep Track Capital, LP 9.90% · 19.25M 股
State Street Global Advisors 6.22% · 12.10M 股
TCG Crossover Management, LLC 5.14% · 10.00M 股
Vanguard Capital Management, LLC 4.87% · 9.47M 股
Vanguard Portfolio Management, LLC 3.77% · 7.33M 股
Marshall Wace LLP 3.52% · 6.84M 股
Viking Global Investors LP 3.44% · 6.70M 股
RA Capital Management, L.P. 3.34% · 6.50M 股
Geode Capital Management, LLC 2.58% · 5.01M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 38次买入 · 12次卖出

姓名职务持股比例
Vipin Garg Chief Executive Officer 0.22%
M. Roberts Chief Scientific Officer 0.06%
Matthew Harris Chief Medical Officer 0.04%
Raymond Jordt Chief Business Officer 0.04%
Jerome Durso Director 0.03%
Gregory Weaver Chief Financial Officer 0.03%
Mitchel Sayare Independent Chairperson 0.01%
Christophe Arbet-Engels Chief Medical Officer 0.01%
John Gill Independent Director 0.01%
Linda Richardson Chief Commercial Officer 0.01%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-30 Gregory Weaver Chief Financial Officer Derivative Exercise and Sale -4,379 $2.76
2026-09-30 Gregory Weaver Chief Financial Officer Derivative Exercise and Retained +10,096 --
2026-09-30 Christophe Arbet-Engels Chief Medical Officer Derivative Exercise and Sale -12,679 $2.76
2026-09-30 Christophe Arbet-Engels Chief Medical Officer Derivative Exercise and Retained +24,821 --
2026-09-15 Linda Richardson Chief Commercial Officer Derivative Exercise and Sale -6,826 $3.24
2026-09-15 Linda Richardson Chief Commercial Officer Derivative Exercise and Retained +17,174 --
2026-08-12 Jerome Durso Director Open Market Acquisition +15,000 $2.95
2026-07-30 Gregory Weaver Chief Financial Officer Other Acquisition +1,753 $2.41
2026-07-30 M. Roberts Chief Scientific Officer Other Acquisition +875 $2.41
2026-04-30 Mitchel Sayare Independent Chairperson Other Derivative Acquisition +48,800 $2.82
2026-04-30 John Gill Independent Director Other Derivative Acquisition +48,800 $2.82
2026-04-30 Philip Hodges Independent Director Other Derivative Acquisition +48,800 $2.82
2026-04-30 Klaus Schafer Independent Director Other Derivative Acquisition +48,800 $2.82
2026-04-30 Catherine Sohn Independent Director Other Derivative Acquisition +48,800 $2.82
2026-04-30 Wayne Pisano Independent Director Other Derivative Acquisition +48,800 $2.82
2026-04-30 Diane Jorkasky Independent Director Other Derivative Acquisition +48,800 $2.82
2026-04-30 Teri Lawver Director Other Derivative Acquisition +48,800 $2.82
2026-04-05 John Gill Independent Director Open Market Acquisition +9,200 $3.41
2026-03-31 Gregory Weaver Chief Financial Officer Open Market Acquisition +10,000 $3.15
2026-03-31 Jerome Durso Director Open Market Acquisition +15,000 $3.14

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:57:34 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

艾尔免疫 讨论区 0 条评论

发表评论